Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 1 050.31 USD -1.12%
Market Cap: 992.9B USD
Section:
 

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is 366.48 USD. Compared to the current market price of 1 050.31 USD, Eli Lilly and Co is Overvalued by 65%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
Base Case
366.48 USD
Overvaluation 65%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

16.7
P/S
P/S
Price to Sales
16.7
vs History
23
vs Industry
9
Median 3Y
16.1
Median 5Y
13.1
Industry
2.6
Forward
15.4
More Details
54.1
P/E
P/E
Price to Earnings
54.1
vs History
46
vs Industry
5
Median 3Y
69.1
Median 5Y
53.2
Industry
21.6
Forward
43.5
More Details
62
P/OCF
P/OCF
Price to OCF
62
vs History
42
vs Industry
5
Median 3Y
81.4
Median 5Y
50.8
Industry
16.5
More Details
56.7
P/FCFE
P/FCFE
Price to FCFE
56.7
vs History
53
vs Industry
5
Median 3Y
84.2
Median 5Y
62.8
Industry
22.5
More Details
41.9
P/B
P/B
Price to Book Value
41.9
vs History
34
vs Industry
0
Median 3Y
46.5
Median 5Y
35.3
Industry
2.3
More Details
17.2
EV/S
EV/S
Enterprise Value to Sales
17.2
vs History
23
vs Industry
8
Median 3Y
16.6
Median 5Y
13.7
Industry
2.9
Forward
15.9
More Details
20.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
20.7
vs History
28
vs Industry
9
Median 3Y
20.7
Median 5Y
16.5
Industry
5.5
More Details
36
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
36
vs History
39
vs Industry
7
Median 3Y
47.2
Median 5Y
33.9
Industry
13
Forward
35.6
More Details
38.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
38.6
vs History
47
vs Industry
8
Median 3Y
54.1
Median 5Y
37.4
Industry
16.6
Forward
38.2
More Details
63.5
EV/OCF
EV/OCF
Enterprise Value to OCF
63.5
vs History
44
vs Industry
5
Median 3Y
84.1
Median 5Y
52.7
Industry
15.8
More Details
158.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
158.4
vs History
6
vs Industry
0
Median 3Y
-190.3
Median 5Y
46.5
Industry
19.1
More Details
10.1
EV/IC
EV/IC
Enterprise Value to IC
10.1
vs History
25
vs Industry
8
Median 3Y
9.8
Median 5Y
8.1
Industry
1.9
More Details

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
NYSE:LLY
988.4B USD 16.7 54.1 36 38.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
514B USD 5.6 20.4 16.7 21.7
CH
Roche Holding AG
SIX:ROG
255.9B CHF 4.2 27.1 11.6 13.5
UK
AstraZeneca PLC
LSE:AZN
209.3B GBP 4.8 29.8 108.2 158.3
CH
Novartis AG
SIX:NOVN
207B CHF 4.6 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
242B USD 3.8 12.7 9.1 10.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.4 9.4 10.9
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
146B USD 2.3 14.8 7.5 10.3
FR
Sanofi SA
PAR:SAN
98.7B EUR 1.5 7.2 6.5 6.5
P/E Multiple
Earnings Growth PEG
US
Eli Lilly and Co
NYSE:LLY
Average P/E: 22
54.1
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.4
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.1
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
12.7
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
FR
Sanofi SA
PAR:SAN
7.2
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBITDA: 399.5
36
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.7
9%
1.9
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.4
2%
4.7
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
FR
Sanofi SA
PAR:SAN
6.5
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBIT: 1 710.7
38.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.7
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.8
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3
FR
Sanofi SA
PAR:SAN
6.5
15%
0.4

See Also

Summary
LLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
LLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LLY stock valuation using valuation multiples.
Wall Street Estimates
LLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.